CANCER:

Uveal Melanoma

Related cancers:

‹

Melanoma (851)

Ocular Melanoma (84)

Cutaneous Melanoma (74)

Mucosal Melanoma (26)

Melanoma (851)

Ocular Melanoma (84)

Cutaneous Melanoma (74)

Mucosal Melanoma (26)

›

No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	TC Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	dacarbazine Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	temozolomide Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	albumin-bound paclitaxel Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	nivolumab + ipilimumab Sensitive: A2 - Guideline
No biomarker No biomarker	Uveal Melanoma Uveal Melanoma	CaT Sensitive: A2 - Guideline
HLA-A positive HLA-A positive	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: B - Late Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C2 – Inclusion Criteria
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: C2 – Inclusion Criteria
MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials
CXCL10 elevation CXCL10 elevation	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	IDE196 Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	nivolumab Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: C3 – Early Trials
LDH-H LDH-H	Uveal Melanoma Uveal Melanoma	ipilimumab Sensitive: C3 – Early Trials
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: C3 – Early Trials
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	cabozantinib capsule Sensitive: C3 – Early Trials
DDX43 overexpression DDX43 overexpression	Uveal Melanoma Uveal Melanoma	selumetinib Resistant: C3 – Early Trials
KRAS overexpression KRAS overexpression	Uveal Melanoma Uveal Melanoma	selumetinib Resistant: C3 – Early Trials
NRAS overexpression NRAS overexpression	Uveal Melanoma Uveal Melanoma	selumetinib Resistant: C3 – Early Trials
PCSK9 underexpression PCSK9 underexpression	Uveal Melanoma Uveal Melanoma	Immunotherapy Sensitive: C3 – Early Trials
IL6 elevation IL6 elevation	Uveal Melanoma Uveal Melanoma	IMCgp100 Sensitive: C3 – Early Trials
GNAQ G48L + FGFR4 C172G GNAQ G48L + FGFR4 C172G	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: C4 – Case Studies
MBD4 mutation MBD4 mutation	Uveal Melanoma Uveal Melanoma	pembrolizumab Sensitive: C4 – Case Studies
MBD4 L563T MBD4 L563T	Uveal Melanoma Uveal Melanoma	pembrolizumab + ipilimumab Sensitive: C4 – Case Studies
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	TAK-733 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	TAK-733 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	enzastaurin Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	enzastaurin Sensitive: D – Preclinical
GNRH1 expression GNRH1 expression	Uveal Melanoma Uveal Melanoma	zoptarelin doxorubicin Sensitive: D – Preclinical
CDK9 overexpression CDK9 overexpression	Uveal Melanoma Uveal Melanoma	SNS-032 Sensitive: D – Preclinical
CDK7 overexpression CDK7 overexpression	Uveal Melanoma Uveal Melanoma	SNS-032 Sensitive: D – Preclinical
BAP1 mutation BAP1 mutation	Uveal Melanoma Uveal Melanoma	JNJ 26481585 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	selumetinib + AZD8055 Sensitive: D – Preclinical
BRAF V600E BRAF V600E	Uveal Melanoma Uveal Melanoma	selumetinib + AZD8055 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	selumetinib + AZD8055 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 + AHT956 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	TAK-733 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	trametinib + GSK2126458 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	Tris DBA Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	U0126 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	selumetinib Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	AEB071 Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	trametinib Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	verteporfin Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	binimetinib + AEB071 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	AEB071 + CGM097 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	everolimus + AEB071 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	FR900359 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	JQ-1 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	JQ-1 Sensitive: D – Preclinical
GNA11 mutation GNA11 mutation	Uveal Melanoma Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical
GNAQ mutation GNAQ mutation	Uveal Melanoma Uveal Melanoma	PD-0325901 + AEB071 Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical
GNA11 Q209L GNA11 Q209L	Uveal Melanoma Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical
GNAQ Q209P GNAQ Q209P	Uveal Melanoma Uveal Melanoma	trametinib + hydroxychloroquine Sensitive: D – Preclinical
GNAQ Q209L GNAQ Q209L	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical
CYSLTR2 L129Q CYSLTR2 L129Q	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical
GNAQ R183Q GNAQ R183Q	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical
GNAQ G48V GNAQ G48V	Uveal Melanoma Uveal Melanoma	MEK inhibitor + YM-254890 Sensitive: D – Preclinical

Uveal Melanoma

Associations(81)

Associations
(81)